Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
RISPERIDONE vs ARAKODA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Risperidone is an atypical antipsychotic that antagonizes dopamine D2 receptors and serotonin 5-HT2A receptors. It also has moderate affinity for alpha1-adrenergic and H1-histaminergic receptors, and low affinity for muscarinic receptors.
ARAKODA (tafenoquine) is an 8-aminoquinoline antimalarial agent that inhibits the conversion of Plasmodium protozoa from liver stage to blood stage, thereby preventing relapses. Its exact mechanism may involve interference with electron transport or generation of reactive oxygen species.
Schizophrenia,Bipolar I disorder (acute manic or mixed episodes),Irritability associated with autistic disorder,Adjunctive therapy in major depressive disorder,Tourette syndrome (off-label),Obsessive-compulsive disorder (off-label)
Radical cure (prevention of relapse) of Plasmodium vivax malaria in patients aged 16 years and older who are receiving appropriate antimalarial therapy for acute P. vivax infection
Initial 2 mg orally once daily, titrated to target dose of 4-6 mg orally once daily (or divided twice daily); maximum 16 mg/day. Alternatively, long-acting IM injection: 25 mg IM every 2 weeks.
400 mg orally once daily for 3 days, then 200 mg once daily for maintenance (up to 12 months).
Risperidone: 3 hours (CYP2D6 extensive metabolizers), 20 hours (poor metabolizers); active metabolite 9-hydroxyrisperidone: 21-30 hours; steady-state reached in 5-6 days
Terminal elimination half-life: approximately 14-16 days (range 12-19 days) in healthy adults; this long half-life is due to extensive tissue distribution and slow release from tissues, providing prophylactic coverage for up to 4 weeks after a single dose.
Extensively metabolized in the liver via CYP2D6 and CYP3A4 to 9-hydroxyrisperidone (paliperidone), which has similar pharmacological activity. The parent drug and metabolite are equally active.
Primarily metabolized by CYP2D6 and monoamine oxidase (MAO). Tafenoquine undergoes extensive metabolism including N-dealkylation and oxidation.
Renal (70% as metabolites, 14% as parent drug) and fecal (14%)
Biliary/fecal: ~90% unchanged; renal: <1% unchanged (dose-proportional urinary excretion of tafenoquine is minimal, with most eliminated via feces as unchanged drug and minor metabolites).
Risperidone: 90% bound to albumin and alpha-1-acid glycoprotein; 9-hydroxyrisperidone: 77% bound
~99.5% bound to human serum albumin (HSA); binding is high and saturable, with unbound fraction slightly increasing at high concentrations.
Risperidone: 1-2 L/kg; 9-hydroxyrisperidone: 0.5-1 L/kg; extensive tissue distribution
Apparent Vd: ~2000 L (or ~24-30 L/kg based on 70 kg), indicating extensive tissue distribution (concentrated in red blood cells, liver, lungs, and adipose tissue).
Oral: 70% (tablet), 70% (oral solution); intramuscular: 100% for immediate-release, 28% for long-acting injection relative to oral
Oral: ~100% (absolute bioavailability not formally determined, but absorption is complete with minimal first-pass metabolism; relative bioavailability is high based on AUC and clinical efficacy).
Cr Cl ≥30 m L/min: no adjustment. Cr Cl <30 m L/min: initiate at 0.5 mg orally twice daily for at least 1 week, then increase by 0.5 mg twice daily as tolerated; maximum 3 mg/day.
No dose adjustment required for mild to moderate renal impairment (Cr Cl ≥30 m L/min). Not recommended for severe renal impairment (Cr Cl <30 m L/min) due to lack of data.
Child-Pugh Class A or B: initiate at 0.5 mg orally twice daily, increase cautiously. Class C: avoid or use with extreme caution; no specific established dose.
Contraindicated in Child-Pugh Class B or C. Use with caution in mild hepatic impairment (Child-Pugh Class A) with no dose adjustment.
Adolescents (13-17 yr) with schizophrenia: initial 0.5 mg orally once daily, titrate to 3 mg/day as tolerated. Children (10-17 yr) with bipolar mania: initial 0.5 mg once daily, titrate to 1-2.5 mg/day. Weight-based not standard; use fixed dosing.
Safety and efficacy not established in pediatric patients (<18 years).
Initiate at 0.5 mg orally once daily; increase by 0.5 mg/day increments; target dose 1-2 mg/day; monitor for orthostasis and extrapyramidal symptoms.
No specific dose adjustment; use with monitoring for renal function due to age-related decline and potential for increased adverse effects.
Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Risperidone is not approved for the treatment of dementia-related psychosis.
ARAKODA can cause hemolytic anemia in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency. G6PD testing must be performed before prescribing due to risk of hemolytic anemia.
Increased mortality in elderly patients with dementia-related psychosis,Cerebrovascular adverse events (stroke, TIA) in elderly with dementia,Neuroleptic malignant syndrome (NMS),Tardive dyskinesia,Hyperglycemia and diabetes mellitus,Weight gain,Hyperprolactinemia,Orthostatic hypotension,Seizures,Leukopenia/neutropenia/agranulocytosis,QT interval prolongation,Priapism,Dysphagia,Body temperature dysregulation,Potential for cognitive and motor impairment
Hemolytic anemia in G6PD-deficient patients (contraindicated in G6PD deficiency without prior testing),Methemoglobinemia (rare, monitor for cyanosis and dyspnea),Psychiatric effects including anxiety, depression, and insomnia,Hepatotoxicity (rare, monitor liver function),Use in pregnancy: not recommended (risk of hemolysis in G6PD-deficient fetus),Lactation: avoid if breastfeeding infant is G6PD deficient
Hypersensitivity to risperidone or any component of the formulation
G6PD deficiency (without confirmed normal G6PD activity),Known hypersensitivity to tafenoquine or any 8-aminoquinoline,Use in children <16 years (safety not established),Severe renal impairment (e GFR <30 m L/min),Lactation in infants with G6PD deficiency or unknown G6PD status
Avoid grapefruit and grapefruit juice; may increase risperidone plasma concentrations. Alcohol can potentiate CNS depression and increase risk of side effects. No specific food restrictions; take with or without food. High-fat meals may slightly increase absorption.
Take with a fatty meal to increase absorption. No specific dietary restrictions. Avoid grapefruit juice as it may alter metabolism.
Risperidone is not a major teratogen in humans based on available studies, but there is a slight increase in risk for gestational diabetes and preterm birth. Third-trimester exposure may cause neonatal extrapyramidal symptoms (e.g., agitation, hypertonia, tremors) and withdrawal symptoms (e.g., respiratory distress, feeding difficulties).
FDA Pregnancy Category C. First trimester: animal studies show fetal harm; human data insufficient. Second/third trimester: risk of fetal growth restriction; consider risk-benefit.
Risperidone is excreted into breast milk with a milk-to-plasma (M/P) ratio of approximately 0.5 for the parent drug and 0.3 for the active moiety (risperidone + 9-hydroxyrisperidone). Relative infant dose (RID) is about 2-4% of the maternal weight-adjusted dose. Monitor the infant for sedation, poor feeding, and extrapyramidal effects. The benefit of breastfeeding should be weighed against potential risks.
Excreted in human milk; M/P ratio unknown. Potential for adverse effects in infant; use caution, consider discontinuing breastfeeding.
Increased clearance of risperidone in pregnancy may require dose adjustments. Some studies suggest a dose increase of 20-30% during the second and third trimesters to maintain therapeutic levels. TDM is recommended to guide dosing, with target trough concentrations similar to non-pregnant patients (10-20 ng/m L for the active moiety). Postpartum dose should be reduced to pre-pregnancy levels.
No established dose adjustments; pharmacokinetic changes in pregnancy may require monitoring drug levels and clinical response.
Monitor for orthostatic hypotension, especially during dose titration. Risperidone can cause QTc prolongation; obtain baseline ECG in at-risk patients. Extrapyramidal symptoms (EPS) are dose-dependent; use lowest effective dose. In elderly dementia patients, increased risk of cerebrovascular events; not approved for this indication. Prolactin elevation is common; monitor for gynecomastia, galactorrhea, and sexual dysfunction. Taper slowly to avoid withdrawal dyskinesia.
ARAKODA (tafenoquine) is indicated for radical cure of Plasmodium vivax malaria. Assess G6PD status before prescribing; contraindicated in G6PD-deficient patients due to hemolytic anemia risk. Monitor for methemoglobinemia. Avoid use in pregnancy/lactation. Take with food to enhance absorption.
Take risperidone exactly as prescribed; do not stop suddenly without consulting your doctor.,Avoid alcohol and grapefruit juice as they may affect drug levels and increase side effects.,Rise slowly from sitting or lying down to prevent dizziness from low blood pressure.,Report any involuntary muscle movements, restlessness, or stiffness to your healthcare provider.,Notify your doctor if you experience breast swelling, discharge, or sexual problems.,Do not drive or operate heavy machinery until you know how risperidone affects you.
Take with food to improve absorption.,You must be tested for G6PD deficiency before starting this medication.,Report any signs of anemia, dark urine, or yellowing of eyes/skin.,Avoid use during pregnancy or breastfeeding.,Do not drive if you experience dizziness or blurred vision.
"Carvedilol, a nonselective beta-blocker with alpha1-blocking activity, may enhance the hypotensive effects of risperidone, an atypical antipsychotic with alpha1-adrenergic antagonism. This additive pharmacodynamic interaction can lead to exaggerated blood pressure reduction, orthostatic hypotension, dizziness, and increased risk of syncope, particularly during initial dosing or dose titration. Patients with cardiovascular comorbidity or volume depletion are at heightened risk for adverse outcomes such as falls or cardiac ischemia."
"Cilazapril, an angiotensin-converting enzyme inhibitor (ACEI), reduces angiotensin II production and aldosterone secretion, leading to vasodilation and decreased blood pressure. Risperidone, an atypical antipsychotic, can cause orthostatic hypotension through alpha-1 adrenergic receptor blockade. Concurrent use may result in additive hypotensive effects, increasing the risk of symptomatic hypotension, dizziness, and syncope, particularly at treatment initiation or dose adjustments."
"Coadministration of risperidone and pizotifen may lead to additive anticholinergic and sedative effects due to their overlapping pharmacological profiles. Risperidone, an atypical antipsychotic with histamine H1 receptor antagonist properties, combined with pizotifen, a serotonin antagonist with strong anticholinergic and antihistaminergic activity, can result in excessive sedation, cognitive impairment, and peripheral anticholinergic effects such as dry mouth, constipation, and urinary retention. Clinically, this interaction increases the risk of falls, confusion, and reduced functional status, especially in elderly patients or those with pre-existing central nervous system depression."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about RISPERIDONE vs ARAKODA, answered by our medical review team.
RISPERIDONE is a Atypical Antipsychotic that works by Risperidone is an atypical antipsychotic that antagonizes dopamine D2 receptors and serotonin 5-HT2A receptors. It also has moderate affinity for alpha1-adrenergic and H1-histaminergic receptors, and low affinity for muscarinic receptors.. ARAKODA is a Antimalarial that works by ARAKODA (tafenoquine) is an 8-aminoquinoline antimalarial agent that inhibits the conversion of Plasmodium protozoa from liver stage to blood stage, thereby preventing relapses. Its exact mechanism may involve interference with electron transport or generation of reactive oxygen species.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between RISPERIDONE and ARAKODA depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of RISPERIDONE is: Initial 2 mg orally once daily, titrated to target dose of 4-6 mg orally once daily (or divided twice daily); maximum 16 mg/day. Alternatively, long-acting IM injection: 25 mg IM every 2 weeks.. The standard adult dose of ARAKODA is: 400 mg orally once daily for 3 days, then 200 mg once daily for maintenance (up to 12 months).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between RISPERIDONE and ARAKODA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. RISPERIDONE is classified as Category A/B. Risperidone is not a major teratogen in humans based on available studies, but there is a slight increase in risk for gestational diabetes and preterm birth. Third-trimester exposu. ARAKODA is classified as Category C. FDA Pregnancy Category C. First trimester: animal studies show fetal harm; human data insufficient. Second/third trimester: risk of fetal growth restriction; consider risk-benefit.. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.